Friday, December 07, 2018 8:10:37 PM
Longfellow95,
Last year there was only a contact person.
Contact: Tina Crombie Head of Business Operations tcrombie@adventbio.uk
https://ct.catapult.org.uk/sites/default/files/publication/GMP%20Manufacturing%20Report%202017%2030_12_17%20FINAL.pdf
This year same contact person Tina Crombie but for the first time a Chief Operations Officer= Philippe Pire.
Tina Crombie Head of Business Operations tcrombie@adventbio.uk 0203 627 9960/ 07905 658843
Philippe Pire Chief Operations Officer ppire@adventbio.uk 0203 627 9960
https://ct.catapult.org.uk/sites/default/files/publication/2018%20GMP%20Manufacturing%20Report_FINAL.pdf
I agree,
Ceci est où l'intrigue se corse.
Last year there was only a contact person.
Contact: Tina Crombie Head of Business Operations tcrombie@adventbio.uk
https://ct.catapult.org.uk/sites/default/files/publication/GMP%20Manufacturing%20Report%202017%2030_12_17%20FINAL.pdf
This year same contact person Tina Crombie but for the first time a Chief Operations Officer= Philippe Pire.
Tina Crombie Head of Business Operations tcrombie@adventbio.uk 0203 627 9960/ 07905 658843
Philippe Pire Chief Operations Officer ppire@adventbio.uk 0203 627 9960
https://ct.catapult.org.uk/sites/default/files/publication/2018%20GMP%20Manufacturing%20Report_FINAL.pdf
I agree,
Ceci est où l'intrigue se corse.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
